PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Vascular Medicine0 citations

Impact of lipid-rich plaques in the femoropopliteal artery on limb outcomes in patients undergoing endovascular therapy

View Full Paper
YSYusuke SatoTMTetsuji MorishitaTSTomohiro Shimizu

Key Points

  • The study aims to understand how lipid-rich plaques affect limb outcomes in patients receiving endovascular therapy for femoropopliteal disease.
  • Single-center, prospective noninterventional observational design
  • Included patients undergoing drug-coated balloon angioplasty between July 2022 and November 2024
  • Used near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) for assessment of the femoropopliteal artery
  • Analyzed major adverse limb events, primary patency, and target-vessel revascularization at 12 months.
  • The LRP group had lower freedom from major adverse limb events at 12 months (69.1% vs 92.3%)
  • LRPs had a higher hazard for major adverse limb events (HR: 6.3)
  • Both groups had similar primary patency and freedom from target-vessel revascularization at 12 months
  • LRP was associated with lower primary patency (HR: 5.1) and lower freedom from target-vessel revascularization (HR: 5.3) at 12 months

Abstract

Background: The impact of lipid-rich plaques (LRPs) in the femoropopliteal artery on limb outcomes remains underexplored. We investigated the influence of LRPs on limb outcomes in patients undergoing endovascular therapy (EVT) for femoropopliteal disease. Methods: This single-center, prospective noninterventional observational study included patients undergoing drug-coated balloon angioplasty for femoropopliteal disease between July 2022 and November 2024. Near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) assessment was conducted on the entire femoropopliteal arterial segment. LRP was defined as plaque with a maximum lipid-core burden index in any 4-mm region > 400. The primary outcome was major adverse limb events (MALEs) at 12 months. Secondary outcomes included primary patency and target-vessel revascularization (TVR) at 12 months. TVR was defined as any repeat EVT or surgical bypass of any segment of the target vessel. Results: Fifty participants were divided into LRP ( n = 19) and non-LRP ( n = 31) groups. The LRP group had significantly lower freedom from MALE at 12 months compared with the non-LRP group (69.1%, 95% CI: 35.7–87.6 vs 92.3%, 95% CI: 72.1–98.0, log-rank p = 0.01). LRP was associated with poorer freedom from MALE at 12 months (hazard ratio HR: 6.3, 95% CI: 1.3–38.8, p = 0.02). Both groups showed comparable primary patency and freedom from TVR at 12 months (log-rank p = 0.03 for both). LRP was associated with lower primary patency (HR: 5.1, 95% CI: 0.97–26.7, p = 0.054) and lower freedom from TVR (HR: 5.3, 95% CI: 1.01–27.8, p = 0.049) at 12 months. Conclusion: LRPs were associated with poor 12-month limb outcomes in patients undergoing EVT for femoropopliteal disease. University Hospital Medical Information Network (UMIN) Clinical Trials Registry ID: UMIN000049231 .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sato et al. (2026) studied this question.

synapsesocial.com/papers/69cd7b695652765b073a95f0https://doi.org/10.1177/1358863x261425583
Ask AI
Helpful
Bookmark
Share
View Full Paper